Emergency Department Quality of Care for Sickle Cell Disease in Ontario, Canada: A Population-Based Matched Cohort Study
========================================================================================================================

* Derek C. H. Chan
* Fiona G. Kouyoumdjian
* Andrea J. Pang
* Yue Niu
* Uma H. Athale
* Jacob Pendergrast
* Madeleine M. Verhovsek

## Abstract

**Background** Acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) often leads patients to seek emergency department (ED) care. The landscape of SCD ED care within Canada’s universal and publicly funded healthcare system remains largely undefined. Here, we sought to address this knowledge gap by characterizing the quality of SCD VOC ED and inpatient care in Ontario, Canada.

**Methods** We used population-level health administrative data to identify patients with SCD in Ontario who presented to the ED with SCD VOC (ICD-10-CA code D57.0) from 2006 to 2018. We evaluated ED and inpatient metrics for this population and compared these with a general ED patient population and a validated Crohn’s disease cohort matched by age, sex, neighbourhood income quintile, geography, date range of visit, and ED triage score.

**Results** We identified 2,123 patients who presented to the ED with SCD VOC for a total of 18,712 unscheduled ED visits. Annual ED visit rates ranged from a mean of 2.6 to 14.2 visits per patient, with 4.6% of patients having incurred 38.4% of all SCD VOC ED visits. Subgroup analyses showed that adult patients with SCD VOC visited the ED 2.5 times more than pediatric patients, but their wait times for initial physician assessment were significantly longer (90.6 vs. 51.1 minutes, *p* < 0.0001) with a difference that was disproportionately larger than the reference cohorts. Males with SCD VOC experienced significantly shorter ED and inpatient stays compared to females (e.g. admission length of stay: 4.4 vs. 5.8 days, *p* < 0.0001), but their ED return rates within 30-days were significantly higher (0.89 vs. 0.35 times, *p* < 0.0001) with a difference that was disproportionately larger relative to the reference cohorts. Lower-income neighbourhoods correlated with lower acuity triage scores for SCD VOC visits and increased repeat ED visit rates at more pronounced levels than the reference cohorts. Higher acuity triage scores for adults with SCD VOC correlated with improved metrics for quality of ED and inpatient care with fewer longer-term ED visits.

**Interpretation** Patients with SCD VOC carry a significant burden of acute care needs, with a smaller patient subset whose high ED visit rates have distinctly increased over time in Ontario, Canada. Adults, males and those from lower income quintile neighbourhoods with SCD VOC experienced poorer quality of ED and inpatient care compared to their counterparts, with differences that are disproportionately larger than those found in the general ED population and in patients with Crohn’s disease. Higher acuity triage scoring may improve and standardize the quality of ED care for adult patients with SCD VOC. Future work should address these identified care quality disparities for SCD VOC that remain present within a universal and publicly funded healthcare system.

## Introduction

Sickle cell disease (SCD) is an inherited haemoglobin disorder that is associated with chronic and life-threatening complications and periodically presents with painful vaso-occlusive crises (VOCs). This disease predominantly occurs in people of African, Mediterranean, Middle Eastern and/or Indian ancestry. The acute, unpredictable and debilitating nature of SCD VOCs frequently leads patients to seek emergency department (ED) care, where the quality of care provided within two-tiered healthcare settings is known to be often inconsistent and poor.1–7 For the estimated 5,000 Canadians who have SCD, more than 50% of the affected population reside in the province of Ontario.8,9 Little is known about their quality of ED and inpatient care within Canada, where health care is universal and publicly funded.

Current data on clinical care for Canadians with SCD VOC remain limited. Among the few published studies, all have been limited to single hospital settings. Previous work has shown that the incidence of paediatric SCD VOC correlates with colder temperatures and higher wind speed,10 with a higher chance of hospital admission predicted by a higher acuity pain score at ED triage, older age and increased systolic blood pressure.11 Early work among adults with SCD VOC has identified potential variability in ED triage scoring12 and time incurred before patients receive opioid administration for acute pain,13 leading to a recent trial of an alternative short-stay unit model of care14 as a means to explore ways to close such gaps of inconsistent care.

To characterize the quality of SCD VOC ED and inpatient care provided across Ontario, we pursued a population-level analysis of health administrative datasets in which SCD VOC ED visit rates, triage scores, time to physician assessment, ED disposition, duration of hospital stay and repeat ED visit rates were measured, stratified by various sociodemographic variables, and compared to the general ED patient population and to patients with Crohn’s disease, with the latter group selected on the basis of having an acute-on-chronic course with variable pain episodes leading both pediatric and adult patients from different ethnic backgrounds to seek acute ED care.

## Methods

### Study settings

Between 2006 and 2018, the number of ED facilities in Ontario increased from 171 to 178. Mandated reporting of ED data into the National Ambulatory Care Reporting System (NACRS) and hospital data into the Discharge Abstract Database (DAD) across the province resulted in a full reporting compliance rate (apart from 4 facilities that were excluded from NACRS in 2006 due to data quality issues). EDs and hospital healthcare services in Ontario are universal and publicly funded for all Canadian citizens and permanent residents living in the province through the Ontario Health Insurance Plan (OHIP) while refugee claimants are insured through the Interim Federal Health Program (IFHP). Canadians from outside of Ontario have health care fees charged to their home province’s public insurance program. Private health care insurance is available to non-Canadian citizens. Individuals lacking any insurance coverage are charged directly.

### Patient cohort definitions and matching criteria

We queried NACRS and DAD databases with the ICD-10-CA code D57.0 (Sickle-cell anaemia with crisis) under admitting diagnosis and most responsible diagnosis to identify all patients who presented to the ED with a primary SCD VOC between 2006 to 2018, limited to unscheduled ED visits and to patients covered by OHIP. These datasets were linked using unique encoded identifiers and analyzed at ICES, which is an independent, non-profit research institute whose legal status under Ontario’s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. We derived matched patient cohorts from the general ED patient population and separately for those with Crohn’s disease (*Figure 1A*), with ED visits from the SCD VOC cohort being matched at a 1 to 2.7 ratio to ED visits from the general ED population by age, sex, neighbourhood income quintile, geography (forward sortation area) and date range of visit (−15 to +15 days of each ED visit), and a 1 to 1.75 ratio obtained when additionally matching by ED triage score. SCD VOC ED visits were similarly matched to ED visits from a validated Crohn’s disease patient cohort at a 1 to 1.16 ratio by similar criteria except for using broader geography (census division) and date range of visit (−45 to +45 days of each ED visit) parameters, with a 1 to 1.1 ratio obtained when additionally matching by ED triage score.

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/07/06/2022.07.06.22277294/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2022/07/06/2022.07.06.22277294/F1)

Figure 1: Patients with SCD VOC carry a significant burden of acute care needs.
A) Matched cohort study criteria and patient numbers between SCD VOC and the general ED population (*Match #1*) and between SCD VOC and a validated Crohn’s disease cohort (*Match #2*) without (*left*) and with (*right*) additional CTAS ED triage as a criterion; B) SCD VOC cohort characteristics by sex, age range and type of residence; C) Annual SCD VOC ED visit rates; Matched cohort comparisons based on ED triage score (D), time to initial physician assessment (E), ED disposition (F), and any one-year ED visit frequency between 0–3/yr, 4–9/yr or ≥ 10/yr (G); H) ED visit frequency categories stratified by repeat ED visits within 14- and 30-days; Error bars represent 95% confidence intervals (CI).

### Quality of care metrics

The following ED and hospital metric data were extracted from NACRS and DAD databases: number of ED visits, triage scores, time to physician initial assessment, time from triage to disposition, type of disposition, number of hospital admissions, length of admission for those admitted to hospital, number of repeat ED visits within a 14- and 30-day time window, and number of ED visits within any 1-year period. Stratifying variables and sociodemographic data for extracted metric data included the following: month and year of ED visit, age bracket, triage scores as per the Canadian Triage and Acuity Scale (CTAS), sex (in relation to emerging data suggestive of sex differences in SCD clinical outcomes15), rurality, Ontario’s marginalization indices (neighbourhood income, dependency, deprivation, ethnic concentration, instability),16 immigrant status, Local Health Integration Network, hospital/institute, and number of ED visits within any 1-year period.

### Statistical analyses

Categorical sums and means with 95% confidence intervals were determined for applicable ED and hospital metric data. Differences between means were calculated at the same confidence interval threshold with *p*-values < 0.05 being considered statistically significant. Bivariate regression analyses for the SCD VOC ED patient cohort were conducted using the generalized linear method on Statistical Analysis System (SAS) software with sociodemographic and ED metric stratifiers as independent variables and the following clinically relevant ED and hospital metric outcomes as selected dependent variables: ED disposition (admission versus discharge), length of admitted inpatient stay, repeat ED visit within 30 days, and classification as a high ED user within a 1-year period (≥ 4 visits/year versus 0-3 visits/year).

## Results

### Patients with SCD VOC carry a significant burden of acute care needs, with a smaller patient subset whose high ED visit rates are distinctly increasing over time

We identified 2,123 patients who presented to the ED with SCD VOC for a total of 18,712 ED visits between January 1, 2006 and December 31, 2018, with background characteristics shown in *Table 1*. There were more visits for adults (71.8%) than children (28.2%) and for males (53.1%) than females (46.9%) (*Figure 1B*). ED visit rates varied between a mean of 2.6 to 14.2 visits per patient per year from 2006 to 2018 (*Figure 1C*). The distribution of number of ED visits per year varied substantially across the cohort: 4.6% (*n* = 99) had ≥ 10 visits/year, accounting for 38.4% of all visits, while 20.6% (*n* = 437) had 4–9 visits/year, representing 36.2% of visits, and 67.0% (*n* = 1,423) had 1–3 visits/year, making up the remaining 25.4% of visits. Bivariate regression analyses between various sociodemographic variables with four selected clinically relevant outcomes (ED disposition, length of hospital admission, repeat ED visits within 30 days, any 1-year ED visit frequency) revealed varying significant degrees of association (*Table 2*).

View this table:
[Table 1:](http://medrxiv.org/content/early/2022/07/06/2022.07.06.22277294/T1)

Table 1: Demographic background of identified patients with SCD VOC as of December 31, 2018.

View this table:
[Table 2:](http://medrxiv.org/content/early/2022/07/06/2022.07.06.22277294/T2)

Table 2: Bivariate analyses for ED-related clinical outcomes for SCD VOC in Ontario, Canada (2006–2018).

Comparative analyses against matched reference cohorts from the general ED population and separately with patients diagnosed with Crohn’s disease showed that patients with SCD VOC were 5.5 to 13.0 times more likely to be triaged at a higher level of acuity (CTAS 1 or 2 over CTAS 3, 4 or 5) (*Figure 1D*). When further adjusted by including ED triage score into the matching criteria, the time to initial physician assessment for SCD VOC averaged 81.3 minutes (95% CI 79.2–83.3) to 93.9 minutes (95% CI 84.6–103.2), which were 9.1 (95% CI 6.3–11.8, *p* < 0.0001) to 14.9 minutes (95% CI 2.42–27.28, *p* = 0.019) faster than the reference cohorts (*Figure 1E*). Patients with SCD VOC stayed significantly longer in the ED from triage to disposition at means of 442.4 (95% CI 436.2–448.6) to 524.2 minutes (95% CI 499.8–548.6), which averaged 184.9 (95% CI 178.1–191.7, *p* < 0.0001) to 80.1 minutes (95% CI 48.5–111.7, *p* < 0.0001) longer than the reference cohorts. SCD VOC cases were 13.4 to 1.5 times more likely to be admitted to hospital than discharged from the ED compared to the reference cohorts (*Figure 1F*). Among those admitted, the length of hospital stay for SCD VOC averaged 5.2 (95% CI 4.98–5.32) to 6.1 days (95% CI 5.5–6.6), which was 1.2 days (95% CI 0.94 – 1.4, *p* < 0.0001) longer than the general ED population, and statistically equivocal compared to patients with Crohn’s disease (*p* = 0.16). Repeat ED visits after being discharged for SCD VOC within 30-days averaged 0.61 (95% CI 0.57–0.65) to 0.59 visits (95% CI 0.47–0.71), which was 0.28 (95% CI 0.24–0.32, *p* < 0.0001) to 0.37 visits (95% CI 0.25–0.49, *p* < 0.0001) more than the reference cohorts. Over any one-year period, SCD VOC cases were 0.015 to 0.040, 21.5 to 4.7, and at least 55.3 times more likely to incur ED visits within a frequency of 1–3, 4–9, and ≥ 10 visits/year respectively compared to the reference cohorts (no patients with Crohn’s disease had ≥ 10 visits/year) (*Figure 1G*). Subgroup analyses between these various ED visit frequencies revealed no differences in triage scoring or ED disposition. However, higher ED visit frequencies in the SCD VOC cohort generally correlated with longer wait times, longer time between ED triage and disposition, and longer admission length of stay. These visits in the SCD VOC cohort were also more often distinct rather than repeats in nature compared to both reference cohorts (*Figure 1H*).

### Adult patients with SCD VOC have a greater burden of need and are not receiving equal or recommended ED treatment compared to pediatric patients, with differences in quality of care that are disproportionately larger than the general ED population and to patients with Crohn’s disease

Subgroup analyses between adult and pediatric patients showed that annual ED visit rates for adults with SCD VOC were 2.5 to 1.5 times higher compared to pediatric patients, yet only 1.1 to 1.0 times higher in the reference cohorts (*Figure 2A*). 17.7% of adult SCD VOC ED visits were assigned disproportionately lower triage scores (CTAS 3, 4 or 5) compared to pediatric counterparts, a difference that was not observed in the general ED population, but was similar in patients with Crohn’s disease (*Figure 2B*). While the other 68.4% of adult SCD VOC ED visits were triaged at CTAS 1 or 2 compared to 18.2% in the general ED population, adult SCD VOC cases were only assessed at −4.4 minutes (95% CI −6.53–-2.33) sooner (*p* < 0.0001). After adjusting for ED triage score, adult SCD VOC cases waited on average 90.6 (95% CI 88.1–93.1) to 96.8 minutes (95% CI 87.0–106.6) for initial physician assessment, which was 39.5 (95% CI 34.77–44.21, *p* < 0.0001) to 41.1 minutes (95% CI 4.4–77.8, *p* = 0.028) longer than pediatric patients (*Figure 2C*), placing adult patients with SCD VOC well behind clinically recommended targets of receiving first-dose analgesia within 30 minutes of triage or 60 minutes from registration.8,12 Similar findings were mirrored when assessing ED time between triage and disposition between adult and pediatric patients with SCD VOC compared to both reference cohorts (*Figure 2D*). 18.5 to 31.6% of adult SCD VOC cases were disproportionately discharged compared to pediatric counterparts, while only a 2 to 0.4% difference was found in the reference cohorts (*Figure 2E*). Among hospital admissions, adult SCD VOC length of stay averaged 5.8 (95% CI 5.6–6.0) to 6.1 days (95% CI 5.5–6.7), which was 2.2 (95% CI 1.8–2.7, *p* < 0.0001) to 0.66 days (95% CI −1.6–2.9, *p* = 0.58) longer than pediatric patients, while adults from the reference cohorts stayed 0.34 days (95% CI 0.01–0.67, *p* = 0.045) longer to −2.47 days shorter (95% CI −4.46–-0.48, *p* = 0.015) than pediatric patients (*Figure 2F*). Repeat ED visit rates within 30-days for SCD VOC showed more pronounced differences between adult and pediatric patients compared to both reference cohorts (*Figure 2G*). Over any one-year period, adult patients with SCD VOC also incurred a disproportionately larger burden of ED visits, with a ≥ 10 visits/year frequency that did not register in either reference cohorts (*Figure 2H*).

![Figure 2:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/07/06/2022.07.06.22277294/F2.medium.gif)

[Figure 2:](http://medrxiv.org/content/early/2022/07/06/2022.07.06.22277294/F2)

Figure 2: Adult patients with SCD VOC have a greater burden of need and are not receiving equal or recommended ED treatment compared to pediatric patients.
Adult versus pediatric subgroup analyses for A) overall ED visit rate; B) acuity triage CTAS score; C) time to initial physician assessment; D) time in ED between triage and disposition; E) ED disposition; F) hospital admission length of stay; G) repeat ED visits within 14- and 30-days; and H) any one-year ED visit frequency between 0–3/yr, 4–9/yr or ≥ 10/yr; Error bars represent 95% CI.

### Male patients presenting with SCD VOC experience shorter stays in the ED and hospital compared to female patients, but their return rates are disproportionately higher, even when compared to the general ED population and to patients with Crohn’s disease

Sex-based subgroup analyses revealed no significant differences in annual ED visit rates or triage scoring between males and females with SCD VOC. While males in all groups waited slightly less compared to females for initial physician assessment (*Figure 3A*), males with SCD VOC spent −64.5 minutes (95% CI −76.8–-52.1, *p* < 0.0001) less time between ED triage and disposition compared to females, whereas this difference was only −20.4 minutes (95% CI −27.9– −12.9) in the general ED population (*Figure 3B*). 5% of male SCD VOC ED visits were disproportionately discharged compared to females, a difference that was not found in either reference cohorts (*Figure 3C*). Among hospital admissions, males with SCD VOC experienced significantly shorter lengths of stay at 4.4 (95% CI 4.2–4.6) to 4.7 days (95% CI 4.2–5.2), which were −1.40 (95% CI −1.74–-1.06, *p* < 0.0001) to −2.45 days (95% CI −3.6–-1.3, *p* < 0.0001) shorter compared to females, differences that were either more pronounced compared to or absent in the reference cohorts (*Figure 3D*). Males with SCD VOC had a significantly higher repeat ED visit rate within 30-days compared to females with a mean difference of 0.54 visits (95% CI 0.46–0.62, *p* < 0.0001), a finding that was not observed in either reference cohorts (*Figure 3E*). Males with SCD VOC also experienced a disproportionately higher ≥ 10 visits/year frequency over any one-year period with a 3.7 to 14.7% increase over females, while this visit frequency barely registered in the reference cohorts (*Figure 3F*).

![Figure 3:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/07/06/2022.07.06.22277294/F3.medium.gif)

[Figure 3:](http://medrxiv.org/content/early/2022/07/06/2022.07.06.22277294/F3)

Figure 3: Male patients presenting with SCD VOC experience shorter stays in the ED and hospital compared to female patients, but their return rates are disproportionately higher.
Male versus female subgroup analyses for A) time to initial physician assessment; B) time in ED between triage and disposition; C) ED disposition; D) hospital admission length of stay; E) repeat ED visits within 14- and 30-days; and F) any one-year ED visit frequency between 0–3/yr, 4–9/yr or ≥ 10/yr; Error bars represent 95% CI.

### Lower income neighbourhood patients with SCD VOC are associated with lower acuity triage scores and increased repeat ED visits at levels that are more pronounced than the general ED population and to patients with Crohn’s disease

Subgroup analyses by neighbourhood income quintile revealed that the lowest quintile among patients with SCD VOC carried the highest ED visit rates compared to either reference cohorts (*Figure 4A*). Differences between the lowest and highest quintiles for the SCD VOC cohort were disproportionately larger compared to the general ED population, and similar in extent to patients with Crohn’s disease, although this latter comparison was limited by few patients in the highest quintiles. Lower neighbourhood income quintiles among patients with SCD VOC correlated with lower acuity triage scores (CTAS 3, 4 or 5), but this finding was not present in either reference cohorts (*Figure 4B*). No obvious patterns were identified when analyzing time to initial physician assessment, time between triage and disposition, ED disposition, and admission length of stay when these metrics were stratified by neighbourhood income quintile. Lower neighbourhood income quintiles among patients with SCD VOC reflected a higher frequency of repeat ED visits within 30-days with a mean difference of 0.64 visits (95% CI 0.40–0.88) (*p* < 0.0001) between the lowest and highest quintile, which was disproportionately larger than 0.25 visits (95% CI 0.13–0.37) (*p* < 0.0001) in the general ED population, and similar in extent to patients with Crohn’s disease, although this latter comparison was again limited by few patients in the highest quintiles. Lower neighbourhood income quintiles also correlated with a greater number of ED visits for SCD VOC over any one-year period, a pattern that barely registered in either reference cohorts (*Figure 4D*).

![Figure 4:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/07/06/2022.07.06.22277294/F4.medium.gif)

[Figure 4:](http://medrxiv.org/content/early/2022/07/06/2022.07.06.22277294/F4)

Figure 4: Lower income neighbourhood patients with SCD VOC are associated with lower acuity triage scores and increased repeat ED visits.
Neighbourhood income quintile subgroup analysis from the lowest-income (1) to the highest-income quintile (5) by A) ED visit rate; B) acuity triage CTAS score; C) repeat ED visits within 14- and 30-days; and F) any one-year ED visit frequency between 0–3/yr, 4–9/yr or ≥ 10/yr; Error bars represent 95% CI.

### Higher triage scores may act as a structural means to improve and standardize the quality of ED care for adult patients with SCD VOC

Subgroup analyses examining quality of care metrics for the adult SCD VOC cohort after adjusting for triage score showed that CTAS 2 scores (over CTAS 3 or 4) indeed captured patients with high ED visit frequencies (*Figure 5A*) and those with the longest admission length of stay (*Figure 5C*). While adult SCD VOC cases assigned CTAS 2 resulted in a mean −9.2 minutes (95% CI −13.9–-4.5) shorter wait time compared to general adult ED counterparts (*p* = 0.00014), CTAS 4 case comparisons demonstrated that adult SCD VOC cases waited significantly longer by 44.3 minutes (95% CI 18.4–70.2) instead (*p* < 0.0001) (CTAS 3 case comparisons were statistically equivocal) (*Figure 5B*). Only CTAS 2 (over CTAS 3 or 4) scores maintained relatively equivocal repeat ED visit rates within 30-days for adult SCD VOC cases compared to general adult ED counterparts, whereas CTAS 3 or 4 scores resulted in disproportionately higher repeat ED visit rates (*Figure 5E*). Higher acuity triage scores also correlated with a higher likelihood of hospital admission (*Figure 5D*) and fewer cases in the ≥ 10 visits/year bracket that otherwise barely registered in the reference cohorts (*Figure 5F*). This data altogether highlights the influence of SCD VOC-specific triaging parameters and suggests that higher triage scores (i.e. CTAS 2 over CTAS 3 or 4) may structurally result in improved ED quality and standardization of care for adult patients with SCD VOC.

![Figure 5:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/07/06/2022.07.06.22277294/F5.medium.gif)

[Figure 5:](http://medrxiv.org/content/early/2022/07/06/2022.07.06.22277294/F5)

Figure 5: Higher triage scores may act as a structural means to improve and standardize the quality of ED care for adult patients with SCD VOC.
Correlated ED metrics and outcomes based on acuity triage CTAS score for A) ED visit rates; B) time to initial physician assessment; C) ED disposition; D) hospital admission length of stay; E) repeat ED visits within 14- or 30-days; and F) any one-year ED visit frequency between 0–3/yr, 4–9/yr or ≥ 10/yr; Error bars represent 95% CI.

## Interpretation

This population-based study of SCD VOC ED and inpatient quality of care for the last greater decade in Ontario, Canada has identified that patients with SCD VOC carry a significant burden of acute care needs, with a smaller patient subset whose high ED visit rates have distinctly increased over time. We found that adults, males and those from lower income quintile neighbourhoods with SCD VOC received poorer quality of ED and inpatient care compared to their counterparts, with differences that are disproportionately larger than those found in the general ED population and among patients with Crohn’s disease. We also determined that higher acuity triage scoring – specifically CTAS 2 over CTAS 3 or 4 – may structurally improve and standardize the quality of ED care received by adults with SCD VOC. Altogether, these findings raise concern that health inequities specific to patients with SCD VOC remain present within a universal and publicly funded healthcare system, and identifies opportunities for future work to close these gaps of care.

Our observations broadly highlight a need to identify and address determinants of health inequities in at least disease-specific settings. For example, why do adult SCD VOC ED wait times remain comparable to adults in the general ED population despite drastically opposing triage acuity scores? Why are there significantly different lag times for the same CTAS score between adult SCD VOC cases and those from the general ED population? And why does CTAS scoring differ in ways that correlate with neighbourhood income quintiles in SCD VOC but not in other patient populations? These striking differences in how patients with SCD VOC are triaged compared to two closely matched but diverse patient cohorts warrant further consideration of unaccounted factors that include but are not limited to patient and healthcare provider educational backgrounds, the role of structural racism, and/or other unaccounted biases within Canada’s healthcare system. In addition, CTAS score criteria may be better customized for use in disease-specific ways rather than a one-size-fits-all approach, adding to a growing recognition that future efforts for Canadian healthcare reform should focus on particular population health needs,17 especially that of marginalized and underserved patient communities that include SCD VOC.

Our study remains limited in several ways, including our inability to further account for the aforementioned variable data within our health administrative databases. Of note, use of the ICD-10-CA code D57.0 for sickle-cell anaemia with crisis captures other SCD overlapping presentations including acute chest syndrome and splenic sequestration, which may have contributed to some heterogeneity in our cohort establishment. While several potential confounders were adjusted in these analyses, our identified care quality disparities still represent overall static snapshots that cannot be strictly attributed to specific causes with full certainty. As such, our suggestion of uptriaging scores for adult SCD VOC cases may only play a partial and/or temporary role to improve their care on a background of other social determinants that also deserve fundamental attention. Finally, other important clinical metrics such as time to first dose analgesic and/or other medications would have further strengthened our analyses in the ED setting.

In summary, our work provides an evidence-based foundation to guide future quality improvement efforts for better SCD VOC care, shedding light on the particular needs of patients who are experiencing poorer quality of care, and identifies structural opportunities to achieve better healthcare equity reform. We urge patient groups and multidisciplinary stakeholders in policy, clinical and research spheres to respond by working collaboratively to enact changes to improve decision-making in our health administrative systems (e.g. collecting educational and ethnic background data) and in how we can ultimately deliver better and more equitable care to patients (e.g. disease-specific adjustments to ED triage score criteria, quality improvement audits). Considering how well the etiology of SCD is understood and how long Canadian patients with SCD have reported on their negative experiences in our healthcare system, we believe this work importantly addresses and delivers findings that are largely overdue.

## Data Availability

All data produced in the present study are available upon reasonable request to the authors.

## Acknowledgements

The authors thank Alexander Kopp for oversight of work completed by our data analysts, and Jessica Zung and Milena Hadsi-Tosev for statistical advice.

## Footnotes

*   **Funding Statement:** Funding supports for this study were provided by the Division of Hematology & Thromboembolism AFP Student Research Grant through the Department of Medicine at McMaster University, a McMaster Medical Student Research Excellence Scholarship through the Michael G. DeGroote School of Medicine at McMaster University, and a Young Researchers’ Award through the Sickle Cell Awareness Group of Ontario. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC).

*   **Competing Interests:** None declared.

*   Received July 6, 2022.
*   Revision received July 6, 2022.
*   Accepted July 6, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of healthcare for children and adults with sickle cell disease. Am J Hematol 2009;84:323–7.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ajh.21408&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19358302&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F06%2F2022.07.06.22277294.atom) 

2.  2.Haywood C Jr., Tanabe P, Naik R, Beach MC, Lanzkron S. The impact of race and disease on sickle cell patient wait times in the emergency department. Am J Emerg Med 2013;31:651–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajem.2012.11.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23380119&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F06%2F2022.07.06.22277294.atom) 

3.  3.Haywood C Jr., Diener-West M, Strouse J, Carroll CP, Bediako S, Lanzkron S, et al. Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease. J Pain Symptom Manage 2014;48:934–43.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jpainsymman.2014.02.002&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24742787&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F06%2F2022.07.06.22277294.atom) 

4.  4.Pulte D, Lovett PB, Axelrod D, Crawford A, McAna J, Powell R. Comparison of emergency department wait times in adults with sickle cell disease versus other painful etiologies. Hemoglobin 2016;40:330–4.
    
    

5.  5.Kanter J, Gibson R, Lawrence RH, Smeltzer MP, Pugh NL, Glassberg J, et al. Perceptions of US adolescents and adults with sickle cell disease on their quality of care. JAMA Netw Open 2020;3:e206016.
    
    

6.  6.Peterson EE, Salemi JL, Dongarwar D, Salihu HM. Acute care utilization in pediatric sickle cell disease and sickle cell trait in the USA: prevalence, temporal trends, and cost. Eur J Pediatr 2020;179:1701–10.
    
    

7.  7.Shah NR, Bhor M, Latremouille-Viau D, Sharma VK, Puckrein GA, Gagnon-Sanschagrin P, et al. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance – the perspective of private and public payers. J Med Econ 2020;23:1345–55.
    
    

8.  8.Canadian Haemoglobinopathy Association. Consensus statement on the care of patients with sickle cell disease in Canada. Version 2.0. Ottawa; 2015.Available from: [https://www.canhaem.org/wp-content/uploads/2018/05/Sickle-Cell-Consensus.pdf](https://www.canhaem.org/wp-content/uploads/2018/05/Sickle-Cell-Consensus.pdf).
    
    

9.  9.Kim E, Graves E, Tunji Ajayi L, Pendergrast J. How many sickle cell disease patients are there in Ontario? Results of a query of health services administrative databases. Toronto; 2018. Available from: <[https://sicklecellanemia.ca/wp-content/uploads/pdf\_public/ahrq\_sickle\_cell\_abstract\_2018.pdf](https://sicklecellanemia.ca/wp-content/uploads/pdf\_public/ahrq\_sickle_cell_abstract_2018.pdf)>
    
    

10. 10.Rogovik AL, Persaud J, Friedman JN, Kirby MA, Goldman RD. Pediatric vasoocclusive crisis and weather conditions. J Emerg Med 2011;41:559–565.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jemermed.2010.05.006&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20576392&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F06%2F2022.07.06.22277294.atom) 

11. 11.Rogovik AL, Li Y, Kirby MA, Friedman JN, Goldman RD. Admission and length of stay due to painful vasoocclusive crisis in children. Am J Emerg Med 2009;27:797–801.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ajem.2008.06.022&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19683107&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F07%2F06%2F2022.07.06.22277294.atom) 

12. 12.Provincial Council for Maternal and Child Health & Ministry of Health and Long-Term Care. Clinical handbook for sickle cell disease vaso-occlusive crisis. Toronto; 2017. Available from: [http://www.health.gov.on.ca/en/pro/programs/ecfa/docs/hb\_sickle.pdf](http://www.health.gov.on.ca/en/pro/programs/ecfa/docs/hb_sickle.pdf).
    
    

13. 13.Naessens V, Ward R, Kuo KHM. Treatment patterns and outcomes of sickle cell patients with frequent ER visits: a single center experience. Blood 2013;122:1010.
    
    

14. 14.Binding A, Ward R, Phua C, Naessens V, O’Brien T, Bhatia S, et al. An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization. CJEM 2019;21:55– 62.
    
    

15. 15.Masese RV, Bulgin D, Knisely MR, Preiss L, Stevenson E, Hankins JS, et al. Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium. PLoS One 2021;16:e0258638.
    
    

16. 16.Matheson FI, Moloney G, van Ingen T; Ontario Agency for Health Protection and Promotion (Public Health Ontario). 2016 Ontario marginalization index: user guide. 1st revision. Toronto, ON: St. Michael’s Hospital (Unity Health Toronto); 2022. Joint publication with Public Health Ontario.
    
    

17. 17.Martin D, Miller AP, Quesnel-Vallée A, Caron NR, Vissandjée B, Marchildon GP. Canada’s universal health-care system: achieving its potential. Lancet 2018;391:1718–1735.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(18)30181-8&link_type=DOI)